Monday, March 24, 2025 1:55:33 PM
What would be more ideal for Elite, merged with or be acquired by a company like Johnson & Johnson, AstraZeneca, Pfizer, Eli Lilly, etc.?The easiest way for all these big pharma to not have to pay the 25% tariff is to partner up or acquire a US drug manufacturing company like Elite. No major build out is required or waiting for the lengthy regulatory approval process...up and running within days and not years from a new build out to manufacture their existing multi-billion dollar block buster drugs. "J&J's site in Wilson, where it plans to invest more than $2 billion, is expected to create 5,000 jobs during the construction stage, and more than 500 positions across the state.
The site will produce treatments for cancer, immune and neurological diseases, the New-Jersey based company said."https://www.reuters.com/business/jj-plans-invest-more-than-55-billion-us-over-next-four-years-2025-03-21/
CEO Nasrat must know that the most ideal time for a merger / acquisition with all US based drug manufacturing company for sale is now.It is about to get real exciting for all of us Long Elite investors.All of us true LONG ELTP investors are holding on tight to our lottery tickets for early retirement / financial freedom within several months. Good luck to all fortunate enough to discover this gold mine.
The site will produce treatments for cancer, immune and neurological diseases, the New-Jersey based company said."https://www.reuters.com/business/jj-plans-invest-more-than-55-billion-us-over-next-four-years-2025-03-21/
CEO Nasrat must know that the most ideal time for a merger / acquisition with all US based drug manufacturing company for sale is now.It is about to get real exciting for all of us Long Elite investors.All of us true LONG ELTP investors are holding on tight to our lottery tickets for early retirement / financial freedom within several months. Good luck to all fortunate enough to discover this gold mine.
Bullish
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
